MAPT and Alzheimer disease: Unfortunately, over the past 20 years, most present and past clinical trials of Aβ‐targeted therapeutics in sporadic late‐onset forms of AD have failed to show clinical benefits in terms of cognitive function despite reducing brain Aβ volume,4 as well as lacked suitable reflects of tau pathology.